Lexeo Therapeutics (LXEO) Cash from Operations (2022 - 2026)

Lexeo Therapeutics' Cash from Operations history runs 5 years deep, the most recent figure standing at 21144000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 2.63% year-over-year to 21144000.0; the TTM figure through Mar 2026 stood at 97989000.0 (down 11.35% YoY), while the FY2025 annual figure was 98561000.0, down 21.45% from the prior year.
• Cash from Operations came in at 21144000.0 for Q1 2026 at Lexeo Therapeutics, down from 20079000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 13192000.0 in Q2 2023 to a low of 29547000.0 in Q3 2025.
• A 5-year average of 19784142.86 and a median of 19226500.0 in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations plunged 102.6% in 2024 and rose 29.11% in 2025, its largest moves.
• Lexeo Therapeutics' Cash from Operations stood at 16626000.0 in 2022, then climbed by 15.91% to 13981000.0 in 2023, then sank by 102.6% to 28326000.0 in 2024, then grew by 29.11% to 20079000.0 in 2025, then declined by 5.3% to 21144000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 21144000.0, 20079000.0, and 29547000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison